Boehringer Ingelheim’s support for patients with diabetes

Pharmaceutical manufacturer Boehringer Ingelheim has partnered with Lincolnshire Heart Centre to start a new ear in care for patients with diabetes

A new clinic in England aims to improve the outcome for diabetic patients after a heart-attack. The Lincolnshire Heart Centre’s new cardio-diabetic outpatient service will provide ‘a holistic one-stop approach to patient care’, after receiving support from German pharmaceutical manufacturer Boehringer Ingelheim.

 

Boehringer Ingelheim transforms cardiovascular health for diabetes patients

Cardiovascular health issues are more likely in patients with diabetes. In Lincolnshire, England, 33% of patients with diabetes have a recorded history of cardiovascular disease.

A diabetes diagnosis can be shocking for many patients, especially for those who have already had a heart attack or have acute coronary syndrome. Healthcare workers want to make it easier to support patients to better manage their health and help prevent future emergencies. Professor Kelvin Lee, Consultant Interventional Cardiologist and Director of the Cardiovascular Research Programme at United Lincolnshire Hospitals NHS Trust  (ULHT), already knew that patients who have Acute Coronary Syndrome (ACS) with diabetes were not always being followed up by their GPs, putting their health at risk. 

The cardio-diabetic in-reach and outpatient programme will:

  • Streamline the service for post-heart attack patients
  • Allow cross-disciplinary knowledge on cardiology wards
  • Offer optimised medical therapy

“Our partnership with Boehringer Ingelheim has allowed us to use our existing staff, and has included a focus on educating and training our cardiac ACPs, and adapting our current processes to provide a better service for our patients for a more joined up approach to their care.

“We are proud to support the NHS as it continues to design, deliver and evaluate innovative models of care to improve patient outcomes and respond to the secondary prevention challenge,” said Dr Christoph Zehendner, Medical Director at Boehringer Ingelheim. “We share the goal of this dedicated team at Lincolnshire NHS Trust to ensure patients receive holistic personalised care. This partnership project is one of many that Boehringer Ingelheim is supporting to identify innovative models of care to ensure a sustainable future for the NHS.”

 

Boehringer Ingelheim’s vision for improved patient outcomes

Boehringer Ingelheim is proud of the support it has been able to offer the NHS. 

“It is incredibly important to support front line NHS staff now as they address a growing patient backlog and the needs of their communities,” said Dr Naj Rotheram, Medical Lead for Partnerships at Boehringer Ingelheim UK & Ireland. “The dedicated team at ULHT have continued to work tirelessly as well as finding ways to innovate in the way they deliver even better care. 

“It has been a privilege to support them to realise our shared ambition of improving outcomes for patients with diabetes at high risk of cardiovascular events by redesigning an integrated cardio-diabetes service delivering patient-centred optimised care.”

*********************************************

For more insights into Healthcare - check out the latest edition of Healthcare Digital and be sure to follow us on LinkedIn & Twitter.

Other magazines that may be of interest - Manufacturing Magazine. Check out our free upcoming virtual event, Manufacturing LIVE, 6th December 2023.

*********************************************

BizClik is a global provider of B2B digital media platforms that cover 'Executive Communities' for CEO's, CFO's, CMO's, Sustainability Leaders, Procurement & Supply Chain Leaders, Technology & AI Leaders, Cyber Leaders, FinTech & InsurTech Leaders as well as covering industries such as Manufacturing, Mining, Energy, EV, Construction, Healthcare + Food & Drink.

BizClik, based in London, Dubai & New York offers services such as Content Creation, Advertising & Sponsorship Solutions, Webinars & Events.

Share

Featured Articles

Google DeepMind's AlphaFold 3 'is Drug Discovery Boost'

Google DeepMind's AlphaFold 3 is an AI model that can predict the structures and interactions of molecules and will help scientists unlock new medicines

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

UnitedHealth Group CEO Andrew Witty tells stunned US congressional hearing Change Healthcare cyberattack affects third of the US population

Why Sanofi Leads the way on Healthcare Sustainability

How French multinational Sanofi is ensuring delivery of essential medical supplies while being ESG-compliant

Philips Q1 Results hit by $1.1bn Respironics Settlement

Medical Devices & Pharma

Vaccine Breakthrough on Antibiotics Resistant Diseases

Medical Devices & Pharma

Oracle Fusion Cloud Update Boost for Patients

Technology & AI